Recursion Pharmaceuticals, Inc.

Equities

RXRX

US75629V1044

Biotechnology & Medical Research

Market Closed - Nasdaq 21:00:08 17/05/2024 BST 5-day change 1st Jan Change
9.415 USD -1.00% Intraday chart for Recursion Pharmaceuticals, Inc. +9.48% -4.51%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Recursion Pharmaceuticals Says BioHive-2 AI Supercomputer Completed MT
Recursion Pharmaceuticals Q1 Loss Widens, Revenue Rises MT
Earnings Flash (RXRX) RECURSION PHARMACEUTICALS Reports Q1 Revenue $13.8M, vs. Street Est of $12.7M MT
Recursion Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Recursion Pharmaceuticals Insider Sold Shares Worth $367,007, According to a Recent SEC Filing MT
Recursion Pharmaceuticals Names Najat Khan Chief R&D Officer MT
Recursion Appoints Najat Khan as Chief R&D Officer and Chief Commercial Officer CI
Recursion Pharmaceuticals Insider Sold Shares Worth $537,190, According to a Recent SEC Filing MT
Recursion Pharmaceuticals to Open London Office MT
Correction: Exchange-Traded Funds, Equity Futures Lower Pre-Bell Wednesday as Fears Grow Over Slow Inflation Retreat MT
Correction: Exchange-Traded Funds, Equity Futures Lower Pre-Bell Wednesday as Fears Grow Over Slow Inflation Retreat MT
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Wednesday as Fears Grow Over Slow Inflation Retreat MT
Needham Raises Price Target on Recursion Pharmaceuticals to $17 From $15, Maintains Buy Rating MT
Earnings Flash (RXRX) RECURSION PHARMACEUTICALS Reports Q4 Revenue $10.9M MT
Recursion Pharmaceuticals, Inc. Appoints Kristen Rushton as Chief Business Operations Officer CI
Recursion Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
Recursion Pharmaceuticals Insider Sold Shares Worth $507,985, According to a Recent SEC Filing MT
Nvidia Discloses Stake in Tech Firms, Causing Shares to Rise MT
Nvidia Discloses Investment Stakes in AI Firms; Shares Jump MT
Let's move forward Our Logo
Arm, SoundHound AI shares jump as Nvidia builds stake RE
Recursion Pharmaceuticals Insider Sold Shares Worth $444,981, According to a Recent SEC Filing MT
Recursion Pharmaceuticals, Inc. Announces Transition of Shafique Virani from the Chief Business Officer into Senior Strategic Advisor CI
TD Cowen Starts Recursion Pharmaceuticals With Market Perform Rating MT
Recursion Pharmaceuticals Insider Sold Shares Worth $517,508, According to a Recent SEC Filing MT
Chart Recursion Pharmaceuticals, Inc.
More charts
Recursion Pharmaceuticals, Inc. is a clinical-stage TechBio company decoding biology to industrialize drug discovery. Its Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. The Company integrates physical and digital components as iterative loops of atoms and bits scaling wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate in silico hypotheses into validated insights and novel chemistry. Its clinical programs include REC-994, REC-2282, REC-4881 and REC-3964. REC-994 is an orally bioavailable, superoxide scavenger small molecule being development for the treatment of symptomatic cerebral cavernous malformation (CCM). REC-2282 for the potential treatment of neurofibromatosis type 2. REC-3964 for the prevention of recurrent Clostridioides difficile infection.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
9.42 USD
Average target price
13 USD
Spread / Average Target
+38.00%
Consensus
  1. Stock Market
  2. Equities
  3. RXRX Stock
  4. News Recursion Pharmaceuticals, Inc.
  5. Recursion Pharmaceuticals to Open London Office